Intervention not reported
Death on induction therapy not reported · patients with newly diagnosed AML
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Intervention not reported
Death on induction therapy · patients with newly diagnosed AML
The intervention showed no clear difference in death on induction therapy (moderate certainty).
1 finding from 1 review
Intervention not reported
Death on induction therapy · patients with newly diagnosed AML
The intervention probably leads to higher death on induction therapy (moderate certainty).
1 finding from 1 review
Renal replacement therapy · hospitalized, mechanically ventilated adults with confirmed SARS‐CoV‐2 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical progression: need for NIV, IMV, ECMO, or renal replacement therapy at day 5 (group 5, 6 or 7) · hospitalised individuals with COVID‐19 (moderate to severe disease)
It is very uncertain whether bamlanivimab changes clinical progression: need for NIV, IMV, ECMO, or renal replacement… compared with placebo (very low certainty).
1 finding from 1 review
Thrombocytopenia · All patients with a diagnosis of multiple myeloma
Bortezomib leads to higher adverse Events: Thrombocytopenia ‐ Bortezomib versus no bortezomib… compared with no bortezomib (high certainty).
2 findings from 1 review
Diarrhoea · All patients with a diagnosis of multiple myeloma
Bortezomib probably leads to higher adverse Events: Diarrhoea ‐ Bortezomib versus no bortezomib (same… compared with no bortezomib (moderate certainty).
2 findings from 1 review
Adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no… compared with no bortezomib (low certainty).
1 finding from 1 review
Adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib leads to higher adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no… compared with no bortezomib (high certainty).
1 finding from 1 review
Overall Survival ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma
Bortezomib probably leads to lower overall Survival ‐ Bortezomib versus no bortezomib (same background… compared with no bortezomib (moderate certainty).
1 finding from 1 review
Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma
Bortezomib showed no clear difference in adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib… compared with no bortezomib (high certainty).
1 finding from 1 review
Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib… compared with no bortezomib (low certainty).
1 finding from 1 review
Adverse effects (cardiac) · All patients with a diagnosis of multiple myeloma
Bortezomib showed no clear difference in adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib… compared with no bortezomib (moderate certainty).
1 finding from 1 review
Adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib leads to higher adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib… compared with no bortezomib (high certainty).
1 finding from 1 review
Overall Survival ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib leads to lower overall Survival ‐ Bortezomib versus no bortezomib (different… compared with no bortezomib (high certainty).
1 finding from 1 review
Progression‐free survival (PSF) · All patients with a diagnosis of multiple myeloma
Bortezomib probably leads to lower progression‐Free Survival ‐ Bortezomib versus no bortezomib (same… compared with no bortezomib (moderate certainty).
1 finding from 1 review
Progression‐free survival · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to lower progression‐Free Survival ‐ Bortezomib versus no bortezomib… compared with no bortezomib (low certainty).
1 finding from 1 review
Treatment‐related death ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma
Bortezomib showed no clear difference in treatment‐related death ‐ Bortezomib versus no bortezomib (same… compared with no bortezomib (low certainty).
1 finding from 1 review
Treatment‐related death ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
It is very uncertain whether bortezomib changes treatment‐related death ‐ Bortezomib versus no bortezomib (different… compared with no bortezomib (very low certainty).
1 finding from 1 review
Fatigue · patients with paroxysmal nocturnal hemoglobinuria
1 finding from 1 review